JP2020514349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514349A5 JP2020514349A5 JP2019549542A JP2019549542A JP2020514349A5 JP 2020514349 A5 JP2020514349 A5 JP 2020514349A5 JP 2019549542 A JP2019549542 A JP 2019549542A JP 2019549542 A JP2019549542 A JP 2019549542A JP 2020514349 A5 JP2020514349 A5 JP 2020514349A5
- Authority
- JP
- Japan
- Prior art keywords
- ape1
- ref
- inhibitor
- group
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 12
- 208000017442 Retinal disease Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- -1 3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl Chemical group 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- WEMXCNYTFZUFSB-BUHFOSPRSA-N (2e)-n,n-diethyl-2-[(3-methoxy-1,4-dioxonaphthalen-2-yl)methylidene]pentanamide Chemical compound C1=CC=C2C(=O)C(\C=C(/CCC)C(=O)N(CC)CC)=C(OC)C(=O)C2=C1 WEMXCNYTFZUFSB-BUHFOSPRSA-N 0.000 claims 2
- HVWUGMMHPTXECQ-ZHACJKMWSA-N (2e)-n-methoxy-2-[(3-methoxy-1,4-dioxonaphthalen-2-yl)methylidene]pentanamide Chemical compound C1=CC=C2C(=O)C(\C=C(/CCC)C(=O)NOC)=C(OC)C(=O)C2=C1 HVWUGMMHPTXECQ-ZHACJKMWSA-N 0.000 claims 2
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 claims 2
- 101710109420 DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 claims 2
- 102100031780 Endonuclease Human genes 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- DPHUWDIXHNQOSY-UHFFFAOYSA-N napabucasin Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(C(=O)C)=C2 DPHUWDIXHNQOSY-UHFFFAOYSA-N 0.000 claims 2
- 229950011456 napabucasin Drugs 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 2
- 229960000215 ruxolitinib Drugs 0.000 claims 2
- 230000027832 depurination Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762473528P | 2017-03-20 | 2017-03-20 | |
| US62/473,528 | 2017-03-20 | ||
| US201762521082P | 2017-06-16 | 2017-06-16 | |
| US62/521,082 | 2017-06-16 | ||
| PCT/US2018/023346 WO2018175429A1 (en) | 2017-03-20 | 2018-03-20 | Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514349A JP2020514349A (ja) | 2020-05-21 |
| JP2020514349A5 true JP2020514349A5 (https=) | 2021-03-18 |
Family
ID=63586117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549542A Pending JP2020514349A (ja) | 2017-03-20 | 2018-03-20 | 癌の処置のための併用治療剤におけるａｐｅ１／ｒｅｆ−１阻害剤の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20190160034A1 (https=) |
| EP (2) | EP3430057A4 (https=) |
| JP (1) | JP2020514349A (https=) |
| CA (1) | CA3056240A1 (https=) |
| WO (1) | WO2018175429A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190160034A1 (en) * | 2017-03-20 | 2019-05-30 | Indiana University Research And Technology Corporation | Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer |
| EP3897601A4 (en) * | 2018-12-17 | 2022-08-31 | Indiana University Research And Technology Corporation | TREATMENT OF GASTROINTESTINAL DISEASES AND THEIR SYMPTOMS |
| CA3121645A1 (en) * | 2018-12-20 | 2020-06-25 | Rafael Pharmaceuticals, Inc. | Oral therapy using 6,8-bis-benzylthio-octanoic acid |
| CN111840228A (zh) * | 2019-04-09 | 2020-10-30 | 中国科学院上海药物研究所 | 肿瘤免疫脂质体，其制备方法和用途 |
| WO2021034635A1 (en) * | 2019-08-16 | 2021-02-25 | Rafael Pharmaceuticals, Inc. | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and a glutaminase inhibitor |
| GB201913124D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| GB201913121D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| CN115317619B (zh) * | 2021-05-10 | 2025-10-17 | 北京化工大学 | 一种核酸纳米载药体及其应用 |
| EP4587003A2 (en) | 2022-09-14 | 2025-07-23 | Opus Genetics, Inc. | Salts and esters of apx3330 and therapeutic uses thereof |
| WO2025147565A1 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Treatment of necrotizing enterocolitis and symptoms thereof |
| WO2025231402A1 (en) * | 2024-05-03 | 2025-11-06 | Indiana University Research And Technology Corporation | Methods of inhibiting retinal degeneration |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030229004A1 (en) * | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| AU2008304619C1 (en) * | 2007-09-26 | 2020-06-04 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
| US11331294B2 (en) * | 2007-09-26 | 2022-05-17 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer |
| KR101982669B1 (ko) * | 2011-05-26 | 2019-05-27 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Ape1 매개된 질환을 치료하기 위한 퀴논 화합물 |
| CN109602734A (zh) * | 2012-03-14 | 2019-04-12 | 印第安纳大学研究及科技有限公司 | 用于治疗白血病的化合物和方法 |
| WO2014047782A1 (zh) * | 2012-09-25 | 2014-04-03 | 鼎泓国际投资（香港）有限公司 | 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用 |
| US20190160034A1 (en) * | 2017-03-20 | 2019-05-30 | Indiana University Research And Technology Corporation | Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer |
| US20190117602A1 (en) * | 2017-04-17 | 2019-04-25 | Indiana University Research And Technology Corporation | Prevention and reversal of inflammation induced dna damage |
| AU2019218797B2 (en) * | 2018-02-08 | 2023-09-21 | Indiana University Research And Technology Corporation | Targeting ocular diseases with novel APE1/Ref-1 inhibitors |
-
2018
- 2018-03-20 US US16/092,812 patent/US20190160034A1/en not_active Abandoned
- 2018-03-20 JP JP2019549542A patent/JP2020514349A/ja active Pending
- 2018-03-20 EP EP18772627.8A patent/EP3430057A4/en not_active Withdrawn
- 2018-03-20 CA CA3056240A patent/CA3056240A1/en active Pending
- 2018-03-20 EP EP20179181.1A patent/EP3735968A1/en not_active Withdrawn
- 2018-03-20 WO PCT/US2018/023346 patent/WO2018175429A1/en not_active Ceased
-
2020
- 2020-09-21 US US17/026,671 patent/US11648226B2/en active Active
-
2023
- 2023-04-05 US US18/295,907 patent/US12350247B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514349A5 (https=) | ||
| CN101686972B (zh) | 治疗用组合物和方法 | |
| JP7818502B2 (ja) | 胃腸間質腫瘍を治療するためのリプレチニブ | |
| CA2970315C (en) | Use of anti-vegf agents to treat lesions in macular degeneration patients | |
| Frampton | Pazopanib: a review in advanced renal cell carcinoma | |
| JP2017528507A5 (https=) | ||
| JP2012525415A5 (https=) | ||
| JP2010509369A5 (https=) | ||
| CN110891953A (zh) | 吡咯并三嗪类衍生物、其制备方法及其用途 | |
| JP2016513097A5 (https=) | ||
| JP2015528454A5 (https=) | ||
| CN107635555B (zh) | 丁螺环酮代谢物的用途 | |
| JP2016027060A5 (https=) | ||
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2014065696A5 (https=) | ||
| JP2006508953A5 (https=) | ||
| JP2012236857A5 (https=) | ||
| CN115803328A (zh) | 哌嗪-2,3-二酮衍生物及其在医药上的应用 | |
| JP2021513517A5 (https=) | ||
| JP2023522010A5 (https=) | ||
| JP2013500977A5 (https=) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| CN115697386A (zh) | 一种治疗帕金森病的方法和药物 | |
| CN116113416A8 (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JP2020516663A5 (https=) |